Advertisement
Advertisement
U.S. markets open in 7 hours 52 minutes
Advertisement
Advertisement
Advertisement
Advertisement

HTG Molecular Diagnostics, Inc. (HTGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
3.0100+0.1900 (+6.74%)
At close: 04:00PM EDT
3.0300 +0.02 (+0.66%)
After hours: 07:51PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close2.8200
Open2.8400
Bid0.0000 x 1000
Ask0.0000 x 1300
Day's Range2.8001 - 3.0500
52 Week Range2.3880 - 24.9600
Volume85,545
Avg. Volume1,268,572
Market Cap3.232M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-27.0900
Earnings DateMar 27, 2023 - Mar 31, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HTGM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HTG Molecular Diagnostics, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

    TUCSON, Ariz., Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of its drug discovery business unit, including the filing of a patent application directed towards its first therapeutics target, and announced that its management team will be hosting in-person meetings at

  • GlobeNewswire

    HTG Announces Certain Preliminary 2022 Unaudited Financial Results

    Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for

  • GlobeNewswire

    HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series

    TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis,” hosted on Tuesday, December 13, 2022. In this latest webinar, Dr. Robert Spitale of the University

Advertisement
Advertisement